New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 30, 2017 – Arbor Pharmaceuticals announced the FDA approval of Triptodur (triptorelin) extended-release injectable suspension for the treatment of pediatric patients ≥ 2 years of age with central precocious puberty (CPP).
Download PDF
Return to publications
